Clinical Trial Update: Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing Pylera BID dosing for Helicobacter pylori eradication has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Pylera (bismuth subcitrate potassium; metronidazole; tetracycline)

Snippet

Sponsor: Forest Laboratories | Conditions: Helicobacter Pylori Infection | Phase 3 | Status: WITHDRAWN